GW Pharma clinical trial data on Epidiolex efficacy and safety
GW Pharma clinical trial data on Epidiolex efficacy and safety The passage contains only publicly available trial results for a pharmaceutical product, with no mention of influential actors, financial flows, or misconduct. It offers no actionable investigative leads. Key insights: Epidiolex (CBD) reduced drop seizures by 42% vs 17% for placebo in a Phase III trial.; Dose‑response observed: 20 mg/kg showed greater reduction than 10 mg/kg.; Adverse events were more common in the treatment arms but generally manageable.
Summary
GW Pharma clinical trial data on Epidiolex efficacy and safety The passage contains only publicly available trial results for a pharmaceutical product, with no mention of influential actors, financial flows, or misconduct. It offers no actionable investigative leads. Key insights: Epidiolex (CBD) reduced drop seizures by 42% vs 17% for placebo in a Phase III trial.; Dose‑response observed: 20 mg/kg showed greater reduction than 10 mg/kg.; Adverse events were more common in the treatment arms but generally manageable.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.